Greylin Investment Mangement Inc Gilead Sciences, Inc. Transaction History

Greylin Investment Mangement Inc

$566 Million
Q2 2024

A detailed history of Greylin Investment Mangement Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Greylin Investment Mangement Inc holds 54,344 shares of GILD stock, worth $4.9 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares

54,344

Previous 64,368 15.57%

Holding current value

$4.9 Million

Previous $4.71 Million 20.92%

% of portfolio

0.66%

Previous 0.8%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$63.15 - $72.88 $633,015 - $730,549	-10,024 Reduced 15.57%	54,344 $3.73 Million
Q1 2024 Apr 24, 2024	SELL	$71.58 - $87.29 $2.31 Million - $2.82 Million	-32,265 Reduced 33.39%	64,368 $4.71 Million
Q4 2023 Jan 25, 2024	SELL	$73.27 - $83.09 $1.73 Million - $1.96 Million	-23,560 Reduced 19.6%	96,633 $7.83 Million
Q3 2023 Oct 10, 2023	SELL	$73.94 - $80.67 $1.62 Million - $1.76 Million	-21,862 Reduced 15.39%	120,193 $9.01 Million
Q2 2023 Jul 10, 2023	SELL	$76.01 - $86.7 $1.71 Million - $1.95 Million	-22,464 Reduced 13.65%	142,055 $10.9 Million
Q1 2023 Apr 07, 2023	SELL	$77.31 - $88.08 $535,371 - $609,954	-6,925 Reduced 4.04%	164,519 $13.7 Million
Q4 2022 Jan 25, 2023	SELL	$62.32 - $89.47 $1.14 Million - $1.64 Million	-18,290 Reduced 9.64%	171,444 $0
Q3 2022 Oct 13, 2022	SELL	$59.54 - $68.01 $3.78 Million - $4.31 Million	-63,422 Reduced 25.05%	189,734 $11.7 Million
Q2 2022 Jul 11, 2022	BUY	$57.72 - $65.01 $1.42 Million - $1.6 Million	24,586 Added 10.76%	253,156 $15.6 Million
Q1 2022 May 20, 2022	BUY	$57.92 - $72.58 $2.38 Million - $2.99 Million	41,130 Added 21.94%	228,570 $13.6 Million
Q4 2021 Feb 15, 2022	SELL	$64.88 - $73.64 $19,464 - $22,092	-300 Reduced 0.16%	187,440 $13.6 Million
Q3 2021 Oct 13, 2021	BUY	$67.69 - $73.03 $110,334 - $119,038	1,630 Added 0.88%	187,740 $13.1 Million
Q2 2021 Jul 14, 2021	BUY	$63.47 - $69.35 $5.37 Million - $5.87 Million	84,629 Added 83.39%	186,110 $12.8 Million
Q1 2021 May 12, 2021	BUY	$60.0 - $68.46 $270,720 - $308,891	4,512 Added 4.65%	101,481 $6.56 Million
Q4 2020 Jan 14, 2021	BUY	$56.65 - $64.55 $572,334 - $652,148	10,103 Added 11.63%	96,969 $5.65 Million
Q3 2020 Oct 13, 2020	BUY	$62.1 - $78.08 $4.86 Million - $6.11 Million	78,204 Added 902.84%	86,866 $5.49 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $54,978 - $63,840	-760 Reduced 8.07%	8,662 $666,000
Q1 2020 Apr 09, 2020	SELL	$62.63 - $80.22 $348,535 - $446,424	-5,565 Reduced 37.13%	9,422 $704,000
Q4 2019 Jan 09, 2020	BUY	$61.62 - $67.78 $17,253 - $18,978	280 Added 1.9%	14,987 $974,000
Q3 2019 Oct 11, 2019	SELL	$62.51 - $69.0 $21,253 - $23,460	-340 Reduced 2.26%	14,707 $932,000
Q2 2019 Aug 15, 2019	BUY	$61.87 - $69.38 $222,732 - $249,767	3,600 Added 31.45%	15,047 $1.02 Million
Q1 2019 Apr 09, 2019	BUY	$62.53 - $70.05 $312 - $350	5 Added 0.04%	11,447 $744,000
Q4 2018 Jan 14, 2019	SELL	$60.54 - $79.0 $7.96 Million - $10.4 Million	-131,460 Reduced 91.99%	11,442 $716,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $84,466 - $93,520	-1,185 Reduced 0.82%	142,902 $11 Million
Q2 2018 Aug 07, 2018	BUY	$64.88 - $75.68 $4.21 Million - $4.91 Million	64,920 Added 82.0%	144,087 $10.2 Million
Q1 2018 May 14, 2018	BUY	$72.84 - $88.8 $2.21 Million - $2.69 Million	30,330 Added 62.1%	79,167 $5.97 Million
Q4 2017 Jan 16, 2018	BUY	$71.15 - $83.52 $1.64 Million - $1.93 Million	23,060 Added 89.46%	48,837 $3.5 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $1.86 Million - $2.2 Million	25,777	25,777 $2.09 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Greylin Investment Mangement Inc, based on Form 13F filings with the SEC.

News

Stay updated on Greylin Investment Mangement Inc with notifications on news.

Account

Greylin Investment Mangement Inc Gilead Sciences, Inc. Transaction History